Lecarnita solution for injection 1g/5ml, 5 ampoules — Made in Greece — Free Delivery

Lecarnita injection solution is used for the treatment of primary and secondary carnitine deficiency in adults and children, including newborns and infants. Secondary carnitine deficiency in patients undergoing hemodialysis.

Suspected secondary carnitine deficiency in patients undergoing hemodialysis in the following cases:

Severe and persistent muscle spasms and / or hypotensive episodes during dialysis;

Energy deficit, which leads to a significant negative impact on the quality of life;

Muscle weakness and / or myopathy;

Cardiopathy;

Anemia, does not respond to erythropoietin treatment, or requires high doses of erythropoietin;

Loss of muscle mass.

Active substance: levocarnitine;

1 ml 200 mg levocarnitine;

Excipients: diluted hydrochloric acid, water for injection.

Hypersensitivity to the components of the preparation.

The preparation is administered intravenously slowly over 2-3 minutes.

Application for congenital metabolic disorders. During therapy, it is advisable to control the level of carnitine and acylcarnitine in both blood plasma and urine. The required dose depends on the specificity of the congenital metabolic disorder and the severity of the manifestations of the disease. In the case of acute decompensation, the recommended dose may be up to 100 mg / kg per day in 3-4 injections. Higher doses can be used if necessary, although side effects such as diarrhea may increase.

Secondary carnitine deficiency in patients undergoing hemodialysis. Before starting therapy, it is necessary to monitor the level of carnitine in the blood plasma. Secondary carnitine deficiency is diagnosed when the ratio of acylcarnitine to free carnitine in blood plasma is more than 0.4 and / or when the concentration of free carnitine is less than 20 μmol / L. A dose of 20 mg / kg should be given as an intravenous bolus at the end of each dialysis session. The overall response should be determined by monitoring plasma levels of acylcarnitine and free carnitine and evaluating the patient's condition. Normalization of the carnitine content in muscle tissue and cardiomyocytes occurs approximately 3 months after reaching the normal concentration of carnitine in the blood plasma. If the introduction of carnitine is stopped, its level will certainly begin to decline again. The need for a repeated saturating course of treatment is determined by quantitative determination of carnitine in blood plasma at regular intervals and by monitoring the patient's condition.

Hemodialysis is a supportive therapy. After a saturating course of administration of levocarnitine, a maintenance dose is used - 1 g of the preparation per day orally. On the day of dialysis, the preparation is administered orally at a dose of 1 g immediately after the completion of the next session.

Given the serious consequences of carnitine deficiency for a pregnant woman, the risk of interruption to treatment for the mother is considered greater than the theoretical risk to the fetus if treatment is continued.

The preparation is used in children from the first day of life, including premature babies.